CPT® Code 91321

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use

The CPT® Code 91321 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically designed to combat coronavirus disease (COVID-19). This vaccine utilizes a formulation of messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), with a dosage of 25 mcg per 0.25 mL intended for intramuscular administration. The mRNA component of the vaccine encodes for the spike protein of the SARS-CoV-2 virus, which is crucial for the virus's ability to infect human cells. By introducing this mRNA into the body, the vaccine prompts cells to produce the spike protein, which is then recognized by the immune system as a foreign entity. This recognition triggers an immune response, leading to the production of antibodies that can neutralize the virus upon future exposure. The specific formulation referenced in this code is tailored for pediatric use, targeting children aged 6 months to 11 years. It is important to note that this code is used solely for reporting the supply of the vaccine and does not include the administration of the vaccine, which must be reported separately. The vaccine's formulation includes buffering agents that stabilize the product and maintain its pH, allowing it to be stored at standard refrigerator temperatures, thus ensuring its viability for use in the pediatric population.